NURS 6521 Exam 1 V1 Advanced Pharmacology | Practice Questions with
Answers & Rationales | Walden University [2026/2027]
Ace your initial advanced practice milestone with this comprehensive NURS 6521
Advanced Pharmacology Exam 1 (V1) practice test bank tailored for Walden
University. Master core prescriptive authority guidelines, including pharmacokinetics,
pharmacodynamics, adverse drug reactions, and lifespan modifications for
pediatric, pregnant, and geriatric populations. Every verified question features a
high-yield clinical rationale to sharpen your therapeutic decision-making and secure a
top grade in your MSN/FNP coursework.
1. Which aspect of rational drug selection addresses disease-specific information
by a national medical or nursing organization?
A. Cost
B. A guideline
C. Availability
D. Patient hepatic and renal function
Rationale: Clinical practice guidelines are systematically developed statements created by
national organizations to assist practitioner and patient decisions about appropriate
healthcare for specific clinical circumstances. They provide disease-specific, evidence-
based recommendations that guide rational drug selection .
2. A nurse is providing medication education. Which statement is INCORRECT
regarding patient teaching?
A. Teach the patient the purpose of the drug.
B. Teach the patient where to purchase the drug.
C. Teach the patient the dosing schedule.
D. Teach the patient about adverse reactions.
Rationale: While patients may benefit from knowing where to obtain medications, this is
not a core component of medication education. Essential teaching includes the drug's
purpose, dosing schedule, administration technique, adverse effects, and precautions. The
location of purchase is administrative rather than pharmacological .
3. A medication is a weak base that ionizes at a pH of 4 and lower. The medication
is administered orally. Which of the following statements is accurate?
A. It will be absorbed primarily in the stomach and become ionized once it reaches the
,small intestine.
B. It will be absorbed primarily in the small intestine and become ionized once it reaches
the bloodstream.
C. Whenever it becomes ionized, the drug will attach to an active transport receptor and
be carried into the bloodstream.
D. It will be absorbed in the small intestine and be non-ionized in the bloodstream
and will be able to enter into a lactating woman's breast milk and also return to
the bloodstream from the breast milk.
Rationale: Weak bases are non-ionized (lipid-soluble) in alkaline environments and
ionized (water-soluble) in acidic environments. The small intestine (alkaline) is the primary
absorption site. In the bloodstream (pH 7.4), the drug remains non-ionized, allowing it to
cross into breast milk. The drug can also return from breast milk to the bloodstream,
creating a dynamic equilibrium .
4. A blood pressure drug is small, lipid-soluble, with no charge at all times and is
99% protein-bound. The patient's dose has been titrated and is at the appropriate
dose to maintain good control of his hypertension. Recently, the patient begins to
take daily high doses of an additional OTC drug that is also small, lipid-soluble,
carries no charge and is highly protein-bound. Which of the following is likely to
happen with the introduction of the second drug?
A. The absorption of the blood pressure drug will increase because it is small, lipid-
soluble and has no charge.
B. The blood pressure drug will have decreased effectiveness.
C. The patient will need to be monitored as he may become hypotensive.
D. Since both drugs are small, lipid-soluble and have no charge, they will compete with
each other at the same receptor sites on body tissues.
Rationale: When two highly protein-bound drugs are administered concurrently, they
compete for binding sites on albumin. This displaces one drug from its binding sites,
increasing the free (active) fraction of the displaced drug. With warfarin-like drugs, this
can cause toxicity. In this case, the blood pressure drug's free concentration increases,
potentially causing excessive hypotension .
5. Drug A is an inhibitor of CYP1A2. Drug B, a prodrug, is a substrate of this
enzyme. What is the result on Drug B of the introduction of Drug A?
A. Drug B will be more toxic because it is not metabolized as well.
B. Drug B will have a weakened effect.
C. Drug B will not become water-soluble.
D. This question cannot be answered based on the information provided.
,Rationale: Prodrugs require metabolic activation by enzymes to become therapeutically
active. If Drug A inhibits CYP1A2, less of Drug B will be converted to its active form,
resulting in a weakened therapeutic effect. The drug would not become more toxic
because it is not being converted to the active (and potentially toxic) metabolite .
6. A patient has a SNP that creates greater than normal amounts of very
efficient/active forms of CYP3A4. This is the enzyme that deactivates Drug G.
Which of the following is accurate?
A. Drug G will have increased effectiveness.
B. Drug G will be deactivated more rapidly, potentially leading to therapeutic
failure.
C. Drug G will accumulate and cause toxicity.
D. The genetic variation has no clinical significance.
Rationale: A patient with ultra-rapid metabolism of CYP3A4 will metabolize and
deactivate Drug G more quickly than normal. This can lead to subtherapeutic drug levels
and potential therapeutic failure. This is an example of a pharmacogenomic variation
affecting drug response .
7. A patient with chronic kidney disease (eGFR 32 mL/min) is prescribed a
medication that is primarily renally eliminated. What adjustment should the AG-
PCNP anticipate?
A. Increase the dose to overcome decreased absorption.
B. Administer the drug more frequently.
C. Reduce the dose or extend the dosing interval.
D. No adjustment is necessary; metabolism will compensate.
Rationale: Renal impairment reduces the clearance of drugs excreted by the kidneys,
leading to drug accumulation and increased risk of toxicity. To prevent adverse effects, the
dose should be reduced or the dosing interval extended .
8. Which process describes the movement of a drug from the bloodstream into
body tissues?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: Distribution is the movement of a drug from systemic circulation into tissues
and body fluids. Factors such as blood flow, protein binding, membrane permeability, and
tissue affinity influence the extent of distribution .
, 9. Which organ is responsible for the primary metabolism of most medications?
A. Kidney
B. Lung
C. Liver
D. Pancreas
Rationale: The liver contains cytochrome P450 enzymes responsible for Phase I
metabolism and conjugating enzymes responsible for Phase II metabolism. Hepatic
metabolism transforms drugs into more water-soluble forms for elimination .
10. A patient taking warfarin begins therapy with trimethoprim-sulfamethoxazole.
What is the expected outcome?
A. Decreased warfarin effect
B. Increased risk of bleeding due to warfarin displacement and CYP2C9 inhibition
C. No significant interaction
D. Warfarin will be metabolized more rapidly
Rationale: Trimethoprim-sulfamethoxazole inhibits CYP2C9, which metabolizes warfarin,
leading to increased warfarin levels. It also displaces warfarin from protein binding sites,
further increasing the free (active) drug concentration. This significantly increases the risk
of bleeding .
11. An agonist produces its therapeutic effect by:
A. Blocking receptors
B. Activating receptors
C. Destroying receptors
D. Preventing metabolism
Rationale: Agonists bind to receptors and activate them, producing a physiological
response similar to endogenous substances .
12. A competitive antagonist works by:
A. Destroying receptor sites
B. Competing with agonists for receptor binding
C. Increasing receptor sensitivity
D. Stimulating maximal receptor response
Rationale: Competitive antagonists reversibly occupy receptors without activating them,
preventing agonists from producing their effects. The antagonism can be overcome by
increasing the agonist concentration .
Answers & Rationales | Walden University [2026/2027]
Ace your initial advanced practice milestone with this comprehensive NURS 6521
Advanced Pharmacology Exam 1 (V1) practice test bank tailored for Walden
University. Master core prescriptive authority guidelines, including pharmacokinetics,
pharmacodynamics, adverse drug reactions, and lifespan modifications for
pediatric, pregnant, and geriatric populations. Every verified question features a
high-yield clinical rationale to sharpen your therapeutic decision-making and secure a
top grade in your MSN/FNP coursework.
1. Which aspect of rational drug selection addresses disease-specific information
by a national medical or nursing organization?
A. Cost
B. A guideline
C. Availability
D. Patient hepatic and renal function
Rationale: Clinical practice guidelines are systematically developed statements created by
national organizations to assist practitioner and patient decisions about appropriate
healthcare for specific clinical circumstances. They provide disease-specific, evidence-
based recommendations that guide rational drug selection .
2. A nurse is providing medication education. Which statement is INCORRECT
regarding patient teaching?
A. Teach the patient the purpose of the drug.
B. Teach the patient where to purchase the drug.
C. Teach the patient the dosing schedule.
D. Teach the patient about adverse reactions.
Rationale: While patients may benefit from knowing where to obtain medications, this is
not a core component of medication education. Essential teaching includes the drug's
purpose, dosing schedule, administration technique, adverse effects, and precautions. The
location of purchase is administrative rather than pharmacological .
3. A medication is a weak base that ionizes at a pH of 4 and lower. The medication
is administered orally. Which of the following statements is accurate?
A. It will be absorbed primarily in the stomach and become ionized once it reaches the
,small intestine.
B. It will be absorbed primarily in the small intestine and become ionized once it reaches
the bloodstream.
C. Whenever it becomes ionized, the drug will attach to an active transport receptor and
be carried into the bloodstream.
D. It will be absorbed in the small intestine and be non-ionized in the bloodstream
and will be able to enter into a lactating woman's breast milk and also return to
the bloodstream from the breast milk.
Rationale: Weak bases are non-ionized (lipid-soluble) in alkaline environments and
ionized (water-soluble) in acidic environments. The small intestine (alkaline) is the primary
absorption site. In the bloodstream (pH 7.4), the drug remains non-ionized, allowing it to
cross into breast milk. The drug can also return from breast milk to the bloodstream,
creating a dynamic equilibrium .
4. A blood pressure drug is small, lipid-soluble, with no charge at all times and is
99% protein-bound. The patient's dose has been titrated and is at the appropriate
dose to maintain good control of his hypertension. Recently, the patient begins to
take daily high doses of an additional OTC drug that is also small, lipid-soluble,
carries no charge and is highly protein-bound. Which of the following is likely to
happen with the introduction of the second drug?
A. The absorption of the blood pressure drug will increase because it is small, lipid-
soluble and has no charge.
B. The blood pressure drug will have decreased effectiveness.
C. The patient will need to be monitored as he may become hypotensive.
D. Since both drugs are small, lipid-soluble and have no charge, they will compete with
each other at the same receptor sites on body tissues.
Rationale: When two highly protein-bound drugs are administered concurrently, they
compete for binding sites on albumin. This displaces one drug from its binding sites,
increasing the free (active) fraction of the displaced drug. With warfarin-like drugs, this
can cause toxicity. In this case, the blood pressure drug's free concentration increases,
potentially causing excessive hypotension .
5. Drug A is an inhibitor of CYP1A2. Drug B, a prodrug, is a substrate of this
enzyme. What is the result on Drug B of the introduction of Drug A?
A. Drug B will be more toxic because it is not metabolized as well.
B. Drug B will have a weakened effect.
C. Drug B will not become water-soluble.
D. This question cannot be answered based on the information provided.
,Rationale: Prodrugs require metabolic activation by enzymes to become therapeutically
active. If Drug A inhibits CYP1A2, less of Drug B will be converted to its active form,
resulting in a weakened therapeutic effect. The drug would not become more toxic
because it is not being converted to the active (and potentially toxic) metabolite .
6. A patient has a SNP that creates greater than normal amounts of very
efficient/active forms of CYP3A4. This is the enzyme that deactivates Drug G.
Which of the following is accurate?
A. Drug G will have increased effectiveness.
B. Drug G will be deactivated more rapidly, potentially leading to therapeutic
failure.
C. Drug G will accumulate and cause toxicity.
D. The genetic variation has no clinical significance.
Rationale: A patient with ultra-rapid metabolism of CYP3A4 will metabolize and
deactivate Drug G more quickly than normal. This can lead to subtherapeutic drug levels
and potential therapeutic failure. This is an example of a pharmacogenomic variation
affecting drug response .
7. A patient with chronic kidney disease (eGFR 32 mL/min) is prescribed a
medication that is primarily renally eliminated. What adjustment should the AG-
PCNP anticipate?
A. Increase the dose to overcome decreased absorption.
B. Administer the drug more frequently.
C. Reduce the dose or extend the dosing interval.
D. No adjustment is necessary; metabolism will compensate.
Rationale: Renal impairment reduces the clearance of drugs excreted by the kidneys,
leading to drug accumulation and increased risk of toxicity. To prevent adverse effects, the
dose should be reduced or the dosing interval extended .
8. Which process describes the movement of a drug from the bloodstream into
body tissues?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: Distribution is the movement of a drug from systemic circulation into tissues
and body fluids. Factors such as blood flow, protein binding, membrane permeability, and
tissue affinity influence the extent of distribution .
, 9. Which organ is responsible for the primary metabolism of most medications?
A. Kidney
B. Lung
C. Liver
D. Pancreas
Rationale: The liver contains cytochrome P450 enzymes responsible for Phase I
metabolism and conjugating enzymes responsible for Phase II metabolism. Hepatic
metabolism transforms drugs into more water-soluble forms for elimination .
10. A patient taking warfarin begins therapy with trimethoprim-sulfamethoxazole.
What is the expected outcome?
A. Decreased warfarin effect
B. Increased risk of bleeding due to warfarin displacement and CYP2C9 inhibition
C. No significant interaction
D. Warfarin will be metabolized more rapidly
Rationale: Trimethoprim-sulfamethoxazole inhibits CYP2C9, which metabolizes warfarin,
leading to increased warfarin levels. It also displaces warfarin from protein binding sites,
further increasing the free (active) drug concentration. This significantly increases the risk
of bleeding .
11. An agonist produces its therapeutic effect by:
A. Blocking receptors
B. Activating receptors
C. Destroying receptors
D. Preventing metabolism
Rationale: Agonists bind to receptors and activate them, producing a physiological
response similar to endogenous substances .
12. A competitive antagonist works by:
A. Destroying receptor sites
B. Competing with agonists for receptor binding
C. Increasing receptor sensitivity
D. Stimulating maximal receptor response
Rationale: Competitive antagonists reversibly occupy receptors without activating them,
preventing agonists from producing their effects. The antagonism can be overcome by
increasing the agonist concentration .
